Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

The primary objective of this randomized, double‐blind, parallel‐controlled study (from December 2016 to October 2018) was to evaluate pharmacokinetic (PK) equivalence of adalimumab biosimilar HLX03 and reference adalimumab in healthy volunteers, and to assess safety, and immunogenicity of HLX03. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hong, Wu, Min, Sun, Jixuan, Zhu, Xiaoxue, Li, Cuiyun, Ding, Yanhua, Zhang, Xiaodi, Chai, Katherine, Li, Xiaojiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937819/
https://www.ncbi.nlm.nih.gov/pubmed/33682358
http://dx.doi.org/10.1002/prp2.733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937819/
https://www.ncbi.nlm.nih.gov/pubmed/33682358
http://dx.doi.org/10.1002/prp2.733

Ejemplares similares